Articles from CardioFocus, Inc.

CardioFocus, Inc., a medical device company dedicated to advancing ablation treatment for cardiac arrhythmias, today announced the publication of the 12-month results from the ECLIPSE AF trial in Circulation: Arrhythmia & Electrophysiology, demonstrating an overall 90.2% 12-month freedom from clinically significant atrial arrhythmia among paroxysmal atrial fibrillation (AF) patients undergoing de novo pulmonary vein isolation (PVI) using three commercial contact-force sensing focal catheters with the Centauri™ System’s optimized WAVE1™ pulsed field ablation (PFA) waveform. The system, which has since received CE mark and is commercially available within the EU and UK where over 6000 patients have been successfully treated, was used with the Abbott TactiCath™ Sensor Enabled, Boston Scientific INTELLANAV STABLEPOINT™, and Johnson & Johnson THERMOCOOL SMARTTOUCH™ ablation catheters. Paroxysmal and persistent AF patients were treated in the study and demonstrated an overall 80.2% 12-month freedom from clinically significant atrial arrhythmia. The waveform was optimized with invasive 90-day remapping and demonstrated an overall chronic PVI durability rate of 89%, per pulmonary vein, in patients treated within the optimized PFA cohorts.

CardioFocus, Inc., a medical device company dedicated to advancing ablation treatment for cardiac arrhythmias, today announced the first series of patients treated with the investigational OptiShot™ Pulsed Field Ablation (PFA) System for the treatment of paroxysmal atrial fibrillation as part of the VISION AF clinical trial.